TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

DR3 is a death domain-containing receptor that is upregulated during T cell activation and whose overexpression induces apoptosis and NF-kappaB activation in cell lines. Here we show that an endothelial cell-derived TNF-like factor, TL1A, is a ligand for DR3 and decoy receptor TR6/DcR3 and that its expression is inducible by TNF and IL-1alpha. TL1A induces NF-kappaB activation and apoptosis in DR3-expressing cell lines, while TR6-Fc protein antagonizes these signaling events. Interestingly, in T cells, TL1A acts as a costimulator that increases IL-2 responsiveness and secretion of proinflammatory cytokines both in vitro and in vivo. Our data suggest that interaction of TL1A with DR3 promotes T cell expansion during an immune response, whereas TR6 has an opposing effect.

[1]  A. Chinnaiyan,et al.  Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95 , 1996, Science.

[2]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[3]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[4]  T. Yue,et al.  TL1, a Novel Tumor Necrosis Factor-like Cytokine, Induces Apoptosis in Endothelial Cells , 1999, The Journal of Biological Chemistry.

[5]  R. Siegel,et al.  The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity , 2000, Nature Immunology.

[6]  C. Via.  Kinetics of T cell activation in acute and chronic forms of murine graft-versus-host disease. , 1991, Journal of immunology.

[7]  Yun Hee Cho,et al.  In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. , 2001, The Journal of pharmacology and experimental therapeutics.

[8]  Zheng Wang,et al.  Inhibition of angiogenesis and breast cancer xenograft tumor growth by vegi, a novel cytokine of the tnf superfamily , 1999, International journal of cancer.

[9]  J. Tschopp,et al.  TWEAK can induce cell death via endogenous TNF and TNF receptor 1 , 1999, European journal of immunology.

[10]  H Chen,et al.  Modulation of T-cell responses to alloantigens by TR6/DcR3. , 2001, The Journal of clinical investigation.

[11]  C. Torre,et al.  Rate of nucleologenesis as a measure of gene activity , 1975, Nature.

[12]  J. Tschopp,et al.  Studies on the interaction between TWEAK and the death receptor WSL‐1/TRAMP (DR3) , 2000, FEBS letters.

[13]  D. Goeddel,et al.  A death-domain-containing receptor that mediates apoptosis , 1996, Nature.

[14]  A. Strasser,et al.  Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells , 2001, Current Biology.

[15]  J. Sheridan,et al.  Identification of a ligand for the death-domain-containing receptor Apo3 , 1998, Current Biology.

[16]  N. Kabra,et al.  Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1 , 1998, Nature.

[17]  Jian Ni,et al.  A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis* , 1999, The Journal of Biological Chemistry.

[18]  C. Smith,et al.  A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. , 2001, Immunity.

[19]  J. Beckmann,et al.  Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. , 1998, Immunity.

[20]  J. Tschopp,et al.  TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). , 1997, Immunity.

[21]  A. Thern,et al.  DR3 Regulates Negative Selection during Thymocyte Development , 2001, Molecular and Cellular Biology.

[22]  J. Bell,et al.  LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[24]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[25]  M. Metzker,et al.  Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Bauer,et al.  Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB , 1996, Current Biology.

[27]  B. Aggarwal,et al.  VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  S R Sprang,et al.  The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. , 1992, The Journal of biological chemistry.

[29]  P. Young,et al.  Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. , 1997, Gene.